Abbott Laboratories EV/EBITDA
Data as of August 04, 2026
EV/EBITDA
22.61
Enterprise Value
$210.15B
EBITDA (TTM)
$9.29B
Sector
Health Care
How It's Calculated
22.61 = $210.15B ÷ $9.29B
What This Means
Abbott Laboratories's EV/EBITDA of 22.6 is elevated, which can reflect growth expectations, scarce assets, or cyclical EBITDA.
About Abbott Laboratories
Abbott Laboratories (ABT) operates in the Health Care sector, specifically in Health Care. With a market capitalization of about $182.90B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $107.12, within a 52-week range of $81.97 to $137.49 (-22.1% from the high, +30.7% from the low). Beta of 0.58 indicates relatively lower volatility versus the market.
Trailing profit margin is about 11.7%, signaling a solid profit margin for its industry.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Abbott Laboratories, the ratio should be read with growth, capex needs, and cycle position in Health Care. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 22.61x EV/EBITDA, Abbott Laboratories (ABT) carries an elevated EV/EBITDA multiple that may embed growth expectations or scarcity within its peer set. Enterprise value of about $210.15B and EBITDA near $9.29B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the ABT metrics hub for related valuation pages.
Sector Comparison
Among Health Care names on our S&P 100 coverage, Abbott Laboratories's EV/EBITDA of 22.61 can be compared with peers such as UNH (16.32), CVS (28.97), MDT (16.53). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Health Care stocks.
Key Takeaways
- ABT is grouped in the Health Care sector for peer comparisons.
- Recent beta of 0.58 suggests lower-than-market price sensitivity.
- Trailing profit margin of 11.7% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for ABT.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other ABT Metrics
Frequently Asked Questions
What is ABT's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Abbott Laboratories's ratio is about 22.61 — common for comparing leveraged companies in Health Care.
Is 22.61 high or low vs peers?
Among Health Care peers (e.g. CVS (28.97), MDT (16.53), UNH (16.32)), ABT's 22.61 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →